Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sat · 31 Oct 2026
Standard addition

Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL.

CAR-T therapy extended progression-free survival compared to bispecific antibodies in blood cancers, though it required more healthcare contact in the first year.

This multicenter retrospective comparative cohort examined comparative survival and health-care contact burden with CAR-T versus bispecific antibody therapy. CAR-T was associated with longer progression-free survival but greater first-year health-care contact burden than bispecific antibody therapy.

What the study was

Study design
Multicenter retrospective comparative cohort
Population
228 patients with relapsed or refractory follicular lymphoma
Sample size
228
Category
Treatment Innovation
Maturity
Validated
Journal
Blood advances

Why it surfaced

Retained as a high-priority multicenter retrospective comparative cohort after PubMed abstract review; the score reflects clinical relevance, design strength, novelty, and population need under the v1.3 conservative rubric.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.